Inloggen
Inloggen
Of aanmelden met
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Registreer
Of aanmelden met
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

BIOCRYST PHARMACEUTICALS, INC.

(BCRX)
  Rapport
Vertraagde tijd Nasdaq  -  22:00 23-09-2022
12.36 USD   -2.68%
14/09BioCryst Pharmaceuticals benoemt Chief Medical Officer
MT
14/09BioCryst Pharmaceuticals, Inc. Benoemt Dr. Bill Sheridan tot Chief Development Officer en benoemt Dr. Ryan Arnold tot Chief Medical Officer
CI
31/08BioCryst Pharmaceuticals ontvangt aanwijzing als weesgeneesmiddel voor behandeling van botaandoening
MT
OverzichtKoersenGrafiekenNieuwsRatingsAgendaOndernemingFinanciënConsensusHerzieningenBeursproductenFonds 
OverzichtAl het nieuwsAanbevelingen van analistenAndere talenPersberichtenOfficiële publicatiesSectornieuws
Nieuws in andere talen op BIOCRYST PHARMACEUTICALS, INC.
15/09Parexel Appoints Peyton Howell Chief Operating and Growth Officer; Promotes FDA Veteran..
14/09BioCryst Pharmaceuticals Names Chief Medical Officer
14/09BIOCRYST PHARMACEUTICALS INC : Change in Directors or Principal Officers, Regulation FD Di..
14/09BioCryst Names Dr. Bill Sheridan Chief Development Officer and Appoints Dr. Ryan Arnold..
14/09BioCryst Pharmaceuticals, Inc. Names Dr. Bill Sheridan Chief Development Officer and Ap..
06/09BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
31/08BioCryst to Present at Upcoming Investor Conferences
31/08BioCryst Pharmaceuticals Receives Orphan Drug Designation for Bone Disorder Treatment
31/08FDA Grants Orphan Drug Designation for BioCryst's ALK-2 Inhibitor, BCX9250, for the Tre..
31/08FDA Grants Orphan Drug Designation for BioCryst's ALK-2 Inhibitor, BCX9250, for the Tre..
31/08BioCryst Gets FDA Orphan Status for BCX9250 in Fibrodysplasia Ossificans Progressiva
29/08BioCryst Presents Data Demonstrating >99 Percent Suppression of Alternative Pathway Com..
26/08BioCryst Pharmaceuticals, Inc. - U.S. Government Exercises Option to Purchase Additiona..
26/08BioCryst Presents Data Demonstrating >99 Percent Suppression of Alternative Pathway Com..
26/08Biocryst Presents Data Demonstrating >99% Suppression of Alternative Pathway Complement..
25/08SECTOR UPDATE : Health Care Stocks Edge Higher Pre-Bell Thursday
25/08BioCryst Pharmaceuticals Receives Option Order from US Government for Influenza Treatme..
25/08BIOCRYST PHARMACEUTICALS INC : Regulation FD Disclosure, Other Events, Financial Statement..
25/08U.S. Government Exercises Option to Purchase Additional RAPIVAB® (Peramivir Injection) ..
25/08U.S. Government Exercises Option to Purchase Additional RAPIVAB® (peramivir injection) ..
18/08BioCryst Pharmaceuticals Receives Approval for Orladeyo in Saudi Arabia; Shares Rise Pr..
18/08BioCryst Announces Approval of ORLADEYO® (berotralstat) in Saudi Arabia
18/08Biocryst Pharmaceuticals, Inc. Announces Approval of Orladeyo® (Berotralstat) in Saudi ..
09/08NORTH AMERICAN MORNING BRIEFING : Stocks to -2-
05/08BIOCRYST PHARMACEUTICALS INC Management's Discussion and Analysis of Financial Conditi..
04/08BIOCRYST PHARMACEUTICALS : Second Quarter 2022 Conference Call
04/08SECTOR UPDATE : Health Care Stocks Slipping Ahead of Thursday Close
04/08SECTOR UPDATE : Health Care Stocks Still Struggling in Thursday Markets
04/08SECTOR UPDATE : Health Care Stocks Sputtering Despite Surging Biotechs
04/08BioCryst Pharmaceuticals Reports Wider Q2 Loss, Resumes Enrollment in BCX9930 Clinical ..
04/08BioCryst Pharma Shares Rise 21% After FDA Drops Partial Hold on BCX9930
04/08TRANSCRIPT : BioCryst Pharmaceuticals, Inc., Q2 2022 Earnings Call, Aug 04, 2022
04/08BIOCRYST : Q2 Earnings Snapshot
04/08BIOCRYST PHARMACEUTICALS : Reports Second Quarter 2022 Financial Results and Upcoming Key ..
04/08Earnings Flash (BCRX) BIOCRYST PHARMACEUTICALS Reports Q2 Revenue $65.5M
04/08BIOCRYST PHARMACEUTICALS INC : Results of Operations and Financial Condition, Regulation F..
04/08Biocryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2022
04/08BioCryst Reports Second Quarter 2022 Financial Results and Upcoming Key Milestones
04/08BioCryst Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six ..
04/08BioCryst Resumes Enrollment in BCX9930 Clinical Program
04/08BioCryst Pharmaceuticals, Inc. Resumes Enrollment in BCX9930 Clinical Program
21/07BioCryst to Report Second Quarter 2022 Financial Results on August 4
18/07BioCryst to Present at Upcoming Investor Conference
15/07BioCryst to Present at Upcoming Investor Conference
04/07BioCryst Presents New Data Demonstrating Consistently Low Attack Rates Among HAE Patien..
01/07BioCryst Presents New Data Demonstrating Consistently Low Attack Rates Among HAE Patien..
01/07BioCryst Pharmaceuticals, Inc. Presents New Data Demonstrating Consistently Low Attack ..
23/06BioCryst Announces ORLADEYO (berotralstat) Data to be Presented at European Academy of ..
22/06BioCryst Announces ORLADEYO® (berotralstat) Data to be Presented at European Academy of..
22/06BioCryst Announces ORLADEYO(R) (berotralstat) Data to be Presented at European Academy ..
10/06BioCryst Selects Pint Pharma as Commercial Partner for ORLADEYO (berotralstat) in Latin..
09/06BioCryst Pharmaceuticals, Inc. - FDA Grants Fast Track Designation for BioCryst's ALK-2..
09/06BioCryst Pharmaceuticals Taps Pint Pharma as Commercial Partner for Orladeyo Drug in La..
09/06BioCryst Selects Pint Pharma as Commercial Partner for ORLADEYO® (berotralstat) in Lati..
08/06BioCryst's BCX9250 Secures Fast Track Designation from the US Food and Drug Administrat..
08/06BioCryst Announces Approval of ORLADEYO (berotralstat) by Swissmedic
08/06Biocryst Pharmaceuticals, Inc. Announces FDA Grants Fast Track Designation for ALK-2 In..
08/06FDA Grants Fast Track Designation for BioCryst's ALK-2 Inhibitor, BCX9250
08/06BioCryst Pharma Gets Fast Track Designation for BCX9250
07/06BIOCRYST PHARMACEUTICALS INC : Change in Directors or Principal Officers, Submission of Ma..
07/06BioCryst Pharmaceuticals Says Swiss Drug Regulator Approves Orladeyo to Prevent Angioed..
07/06BioCryst Announces Approval of ORLADEYO® (berotralstat) by Swissmedic
07/06Biocryst Pharmaceuticals, Inc. Announces Approval of Orladeyo(R) (Berotralstat) by Swis..
07/06BioCryst Announces Health Canada has Authorized ORLADEYO (berotralstat), the Only Oral ..
06/06BioCryst Pharmaceuticals Gets Canada's Approval of Oral Treatment to Prevent Hereditary..
06/06BioCryst Announces Health Canada has Authorized ORLADEYO® (berotralstat), the Only Oral..
06/06Biocryst Announces Health Canada Has Authorized Orladeyo® (Berotralstat), the Only Oral..
01/06BioCryst to Present at Upcoming Investor Conferences
10/05TRANSCRIPT : BioCryst Pharmaceuticals, Inc. Presents at Bank of America 2022 Healthcare Co..
09/05BioCryst to Present at Upcoming Investor Conferences
09/05BIOCRYST PHARMACEUTICALS INC Management's Discussion and Analysis of Financial Conditi..
06/05BioCryst to Present at Upcoming Investor Conferences
05/05BioCryst Reports Inducement Grants under Nasdaq Listing Rule 5635(4)
05/05TRANSCRIPT : BioCryst Pharmaceuticals, Inc., Q1 2022 Earnings Call, May 05, 2022
05/05Earnings Flash (BCRX) BIOCRYST PHARMACEUTICALS Reports Q1 Revenue $49.9M, vs. Street Es..
05/05BIOCRYST : Q1 Earnings Snapshot
05/05BIOCRYST PHARMACEUTICALS INC : Results of Operations and Financial Condition, Regulation F..
05/05BioCryst Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended Mar..
05/05BioCryst Reports First Quarter 2022 Financial Results and Upcoming Key Milestones
05/05BioCryst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2022
04/05BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
28/04European Medicines Agency Grants PRIME Designation to BioCryst's ALK-2 Inhibitor, BCX92..
27/04BioCryst Pharmaceuticals' BCX9250 Drug Candidate Secures Access to EU's PRIME Program; ..
27/04European Medicines Agency Grants PRIME Designation to BioCryst's ALK-2 Inhibitor, BCX92..
27/04European Medicines Agency Grants PRIME Designation to BioCryst Pharmaceuticals, Inc.'s ..
21/04BioCryst to Report First Quarter 2022 Financial Results on May 5
18/04BioCryst Pharmaceuticals Shares Drop Midday Following Barclays Downgrade
14/04TRANSCRIPT : BioCryst Pharmaceuticals, Inc. Presents at Needham 21st Annual Healthcare Con..
12/04NORTH AMERICAN MORNING BRIEFING : Stocks Waver, -3-
11/04BioCryst to Present at Upcoming Investor Conference
11/04BIOCRYST PHARMACEUTICALS : Regulation FD Disclosure - Form 8-K
11/04BIOCRYST PHARMACEUTICALS INC : Regulation FD Disclosure (form 8-K)
08/04SECTOR UPDATE : Health Care Stocks Enjoy Late Uptick
08/04Top Midday Decliners
08/04SECTOR UPDATE : Health Care Stocks Firming in Mostly Higher Market
08/04BioCryst Suspends Patient Enrollment in Clinical Trials for BCX9930; Shares Tumble
08/04BIOCRYST PHARMACEUTICALS : Pauses Enrollment in BCX9930 Clinical Trials - Form 8-K
08/04BIOCRYST PHARMACEUTICALS INC : Other Events, Financial Statements and Exhibits (form 8-K)
08/04BioCryst Pharmaceuticals Pauses Enrollment in BCX9930 Clinical Trials, Shares Plummet 2..
08/04BioCryst Pharmaceuticals, Inc. Pauses Enrollment in BCX9930 Clinical Trials
Volgende evenement op BIOCRYST PHARMACEUTICALS, INC.